Since 2010 14% of US accelerated approvals have been granted to Merck & Co’s Keytruda.
The relatively low-key asset might at least partly be responsible for Biocryst shares more than doubling since the start of December.
Entresto can now be used in five million of six million US heart failure patients, but Novartis admits ramp-up in the new population will be slow.
Will it be a new class of cancer drug or another failure for Novartis’s IL-1 inhibitor?
With mounting competition in Her2-directed breast cancer treatment, Zymeworks’ latecomer struggles to show that it’s better.
The US regulator will provide verdicts on cancer projects from TG and Athenex, while Sarepta aims for its third Duchenne approval.